NCT01323972View on ClinicalTrials.gov

Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

May 16, 2011

Primary Completion Date

November 22, 2011

Study Completion Date

May 4, 2012

Conditions
Malaria
Interventions
BIOLOGICAL

GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)

4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process

Trial Locations (2)

Unknown

GSK Investigational Site, Enugu

GSK Investigational Site, Jos

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT01323972 - Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children | Biotech Hunter | Biotech Hunter